Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia.
Uchida M, Ishida S, Mochizuki E, Ozawa N, Yonemitsu H, Ochiai H, Nakamura H, Kawashiri T, Watanabe H, Tsuji T, Suetsugu K, Kato K, Egashira N, Akashi K, Ieiri I.
Uchida M, et al. Among authors: ozawa n.
Cancer Diagn Progn. 2024 Sep 1;4(5):617-622. doi: 10.21873/cdp.10372. eCollection 2024 Sep-Oct.
Cancer Diagn Progn. 2024.
PMID: 39238617
Free PMC article.